Skip to main content
Log in

Serum Anti-Mullerian Hormone (AMH) Levels Among Different PCOS Phenotypes and Its Correlation with Clinical, Endocrine, and Metabolic Markers of PCOS

  • Reproductive Endocrinology: Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Anti-Mullerian hormone (AMH) is one of the direct indicators of follicular pool but no standard cutoff has been defined for diagnosis of polycystic ovary syndrome (PCOS). The present study evaluated the serum AMH levels among different PCOS phenotypes and correlated the AMH levels with clinical, hormonal, and metabolic parameters among Indian PCOS women. Mean serum AMH was 12.39 ± 5.3ng/mL in PCOS cohort and 3.83 ± 1.5 ng/mL in non-PCOS cohort (P < 0.01). Out of 608 PCOS women, 273 (44.9%) women belonged to phenotype A, 230 (37.8%) women were phenotype D. Phenotypes C and B were 12.17% and 5.10% respectively. Among those with the highest AMH group (AMH>20ng/ml; 8.05%), majority belonged to phenotype A. Menstrual cycle length, serum testosterone, fasting total cholesterol levels, and follicle number per ovary had positive correlation with serum anti-Mullerian levels (P < 0.05). AMH cutoff for the diagnosis of PCOS was calculated as ≥ 6.06 ng/mL on ROC analysis with sensitivity and specificity of 91.45% and 90.71% respectively. The study shows high serum AMH levels in PCOS are associated with worse clinical, endocrinological, and metabolic parameters. These levels may be used to counsel patients regarding treatment response, help in individualized management and prediction of reproductive and long-term metabolic outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–97. https://doi.org/10.1016/S0140-6736(07)61345-2.

    Article  CAS  PubMed  Google Scholar 

  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. https://doi.org/10.1016/j.fertnstert.2003.10.004.

    Article  Google Scholar 

  3. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–9. https://doi.org/10.1093/humrep/der297 Epub 2011 Sep 16.

    Article  CAS  PubMed  Google Scholar 

  4. Kim JJ, Hwang KR, Chae SJ, Yoon SH, Choi YM. Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome. Hum Reprod. 2020;35(3):652–9. https://doi.org/10.1093/humrep/deaa012.

    Article  CAS  PubMed  Google Scholar 

  5. Durlinger ALL, Visser JA, Themmen APN. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002;124(5):601–9. https://doi.org/10.1530/rep.0.1240601.

    Article  CAS  PubMed  Google Scholar 

  6. Seifer DB, Maclaughlin DT. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007;88(3):539–46. https://doi.org/10.1016/j.fertnstert.2007.02.014.

    Article  CAS  PubMed  Google Scholar 

  7. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003.

    Article  PubMed  Google Scholar 

  8. Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences. J Obstet Gynaecol Res. 2019;45(12):2330–7. https://doi.org/10.1111/jog.14132.

    Article  PubMed  Google Scholar 

  9. Yue CY, Lu LK, Li M, Zhang QL, Ying CM. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One. 2018;13(8):e0203129. https://doi.org/10.1371/journal.pone.0203129 PMID: 30153296; PMCID: PMC6112651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Atkin SL. Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018;88(2):258–62. https://doi.org/10.1111/cen.13517.

    Article  CAS  PubMed  Google Scholar 

  11. Teede H, Misso M, Tassone EC, Dewailly D, Ng EH, Azziz R, Norman RJ, Andersen M, Franks S, Hoeger K, Hutchison S, Oberfield S, Shah D, Hohmann F, Ottey S, Dabadghao P, Laven JSE. Anti-Müllerian hormone in PCOS: a review informing international guidelines. Trends Endocrinol Metab. 2019;30(7):467–78. https://doi.org/10.1016/j.tem.2019.04.006 Epub 2019 May 31.

    Article  CAS  PubMed  Google Scholar 

  12. Anand S, Kumar A, Prasad A, Trivedi K. Updated meta-analysis on the diagnostic accuracy of serum anti-Mullerian hormone in poly cystic ovary syndrome involving 13 509 subjects. J Obstet Gynaecol Res. 2022;48(8):2162–74. https://doi.org/10.1111/jog.15233 Epub 2022 Apr 8.

    Article  CAS  PubMed  Google Scholar 

  13. Dewailly D, Catteau-Jonard S, Reyss AC, Maunoury-Lefebvre C, Poncelet E, Pigny P. The excess in 2-5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome. Hum Reprod. 2007;22(6):1562–6. https://doi.org/10.1093/humrep/dem060.

    Article  PubMed  Google Scholar 

  14. Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(1):59.e1–8. https://doi.org/10.1016/j.ajog.2014.02.026.

    Article  CAS  PubMed  Google Scholar 

  15. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, Mason H, Nelson SM, Visser JA, Wallace WH, Anderson RA. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–85. https://doi.org/10.1093/humupd/dmt062 Epub 2014 Jan 14. Erratum in: Hum Reprod Update. 2014 Sep-Oct;20(5):804.

    Article  PubMed  Google Scholar 

  16. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10(2):107–17. https://doi.org/10.1093/humupd/dmh010.

    Article  PubMed  Google Scholar 

  17. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009;24(11):2917–23. https://doi.org/10.1093/humrep/dep225.

    Article  CAS  PubMed  Google Scholar 

  18. Skałba P, Cygal A, Madej P, et al. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2011;158(2):254–9. https://doi.org/10.1016/j.ejogrb.2011.06.006.

    Article  CAS  PubMed  Google Scholar 

  19. Jun TJ, Jelani AM, Omar J, Rahim RA, Yaacob NM. Serum anti-Müllerian hormone in polycystic ovary syndrome and its relationship with insulin resistance, lipid profile and adiponectin. Indian J Endocrinol Metab. 2020;24(2):191. https://doi.org/10.4103/ijem.IJEM_305_19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cui Y, Shi Y, Cui L, Han T, Gao X, Chen ZJ. Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome. Fertil Steril. 2014;102(1):230–236.e2. https://doi.org/10.1016/j.fertnstert.2014.03.032.

    Article  CAS  PubMed  Google Scholar 

  21. Gupta M, Yadav R, Mahey R, Agrawal A, Upadhyay A, Malhotra N, Bhatla N. Correlation of body mass index (BMI), anti-Mullerian hormone (AMH), and insulin resistance among different polycystic ovary syndrome (PCOS) phenotypes - a cross-sectional study. Gynecol Endocrinol. 2019;35(11):970–3. https://doi.org/10.1080/09513590.2019.1613640 Epub 2019 May 12.

    Article  CAS  PubMed  Google Scholar 

  22. Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701. https://doi.org/10.1093/humupd/dmu020.

    Article  CAS  PubMed  Google Scholar 

  23. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe AA. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014;29(4):791–801. https://doi.org/10.1093/humrep/det469 Epub 2014 Jan 16.

    Article  CAS  PubMed  Google Scholar 

  24. Ramezani Tehrani F, Rahmati M, Mahboobifard F, Firouzi F, Hashemi N, Azizi F. Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome. Reprod Biol Endocrinol. 2021;19(1):76. https://doi.org/10.1186/s12958-021-00755-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bell RJ, Islam RM, Skiba MA, Herbert D, Martinez Garcia A, Davis SR. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod. 2021;37(1):109–18. https://doi.org/10.1093/humrep/deab232 PMID: 34741176.

    Article  CAS  PubMed  Google Scholar 

  26. Gürsu T, Eraslan A, Angun B. Comparison of body mass index, anti-müllerian hormone and insulin resistance parameters among different phenotypes of polycystic ovary syndrome. Gynecol Obstet Clin Med. 2022;2(4):164–170. https://doi.org/10.1016/j.gocm.2022.10.002.

Download references

Acknowledgements

Reeta Mahey and Neena Malhotra had proposed and planned the idea. Rohitha Cheluvaraju has drafted the idea. Priyanka Prabhakar, Keerthana Rajasekaran, and Deeksha Patkar have helped in data compilation. Ashish Upadhyay has done the statistical analysis. Monika Rajput revised it critically for important intellectual content. All the authors appraised and approved the final manuscript.

Availability of Material

Not applicable

Code Availability

Not applicable

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Reeta Mahey.

Ethics declarations

Ethical Approval

Ethical clearance was taken from the Institute Ethics committee (IEC – 551/06/08/2021) before starting the study.

Consent to Participate and Publication

Informed consent was obtained from all individual participants included in the study for participation and publishing purposes.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malhotra, N., Mahey, R., Cheluvaraju, R. et al. Serum Anti-Mullerian Hormone (AMH) Levels Among Different PCOS Phenotypes and Its Correlation with Clinical, Endocrine, and Metabolic Markers of PCOS. Reprod. Sci. 30, 2554–2562 (2023). https://doi.org/10.1007/s43032-023-01195-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43032-023-01195-y

Keywords

Navigation